Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Medigene presents data on the successful production of AML DC vaccines at AACR conference


Medigene participates at five upcoming conferences


Clinical data for DC vaccine in prostate cancer IIT study presented by Oslo University


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. The share is part of TecDAX, an index of the Deutsche Börse (German Stock Exchange) that includes Germany's most important mid-cap technology companies.

show medigene share


09 May 2018

3-Months Report 2018

15 May 2018

Annual General Meeting 2018

15 - 17 May 2018

16th CIMT Annual Meeting

Mainz, Germany

16 - 19 May 2018

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Chicago, USA

21 - 23 May 2018

UBS Global Life Science Conference

New York, USA

24 - 25 May 2018

3rd Annual Advances in Immuno-Oncology Congress

London, UK

07 Aug 2018

6-Months Report 2018

13 Nov 2018

9-Months Report 2018

Reports & Presentations


Company presentation April 2018

DownLoad (2 MB)


Medigene Presentation on Annual Report 2017

DownLoad (922 KB)


Annual Report 2017

DownLoad (1 MB)

Annual General Meeting 2018

The Annual General Meeting of Medigene shareholders for fiscal year 2017 will be held in German language on Tuesday, 15 May 2018 at "Haus der Bayerischen Wirtschaft", Max-Joseph-Straße 5, 80333 Munich, Germany.

read more

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work (1)

HPLC loading with samples

DownLoad (2 MB)

Laboratory work (2)

Weighing of a substance

DownLoad (8 MB)

Laboratory work (3)

Sampling from a nitrogen tank

DownLoad (9 MB)

Contact person

Julia Hofmann
Senior Director, Head of Public & Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20

Dr. Robert Mayer
Senior Manager Public & Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20